Tags : To

Pharma

Thermo Fisher Expands its Direct-to-Patient Service Offerings

Shots: The company has expanded its Direct-to-Patient service offerings for supporting decentralized clinical trials to lessen clinical trial lengths and costs while increasing patient enrollment and participation rates The company’s expanded Direct-to-Patient services build on its global Clinical Site-to-Patient program that launched in early 2020 to ensure that clinical trial patients have uninterrupted access to […]Read More

Biosimilars Biotech

Amgen and Allergan Report Results of ABP 798 (rituximab, biosimilar)

Shots: The P-I/III (NCT02792699) study involves assessing of ABP 798 vs Rituxan (rituximab, IV) in 311 patients in the ratio (1:1:1) with moderate-to-severe RA, evaluating safety, efficacy, and PK for 48 wks. The study demonstrated in meeting 1EPs as AUC (area under the serum concentration–time curve) and Cmax (maximum serum concentration) with biosimiliarity in PK, efficacy, and safety ABP 798 (rituximab, biosimilar) is […]Read More